The rationale is that MYCN upregulates EZH2, leading to the inactivation of a tumor suppressor program in neuroblastoma [18], while ATRX in-frame fusion neuroblastoma is sensitive to EZH2 inhibition [19]. This evidence concerns the gene EZH2 and neuroblastoma.